09 Jan 2014, BioSpectrum Bureau , BioSpectrum
Singapore: Mundipharma, a pain-management and drug-delivery company launched OxyNorm injections, a product for post-operative pain in China. The introduction of OxyNorm injections is part of Mundipharma's expanding operations offering patient-focused drug treatments throughout the region.
OxyNorm injections are a treatment to manage post-operative pain for patients suffering from moderate-to-severe pain following surgery that may require the use of strong opioids. OxyNorm injections contain the active ingredient oxycodone, which is documented for its analgesic efficacy, with fewer side effects such as nausea, vomiting, nightmares or hallucinations2 and for its rapid onset of action while still remaining a long-standing opioid.
Mr. Peter Zhonglin Wang, General Manager, Mundipharma Greater China, said, "Mundipharma China is focused on bringing innovative products such as OxyNorm injections to patients, to help ease their burden of pain. Pain is inadequately treated in half of all surgical procedures, and in China, the surgery volume is expected to increase from 25 million in 2011 to 38 million in 2016 with 8 percent of patients postponing surgery because of concerns associated with post-operative pain. OxyNorm injections present a way to minimize the discomfort and side effects after surgery for this growing number of patients."
Mr. Raman Singh, Regional Managing Director, Mundipharma Asia, Latin America, Middle East and Africa, stated, "Mundipharma is passionately committed to bringing innovative, effective and safe treatments to patients everywhere. There is a great unmet need in the treatment of pain in China and it is our responsibility as a company to harness innovation to provide patients with easier access to therapeutic strategies to improve the quality of their lives. In fact, more than 80 percent of patients are needlessly experiencing post-operative pain of acute pain with 71 percent of this being moderate-to-severe. OxyNorm injections are an addition to Mundipharma China's portfolio of pain treatment options that will help patients better manage their pain."